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56.1 Introduction
Organ transplantation is the only deﬁnitive treatment for many
critical diseases of the liver, kidney, heart, pancreas, and lungs.
Although it is the primary therapeutic option at present, trans­
planted patients have to deal with the numerous side effects of
life-long dependence on immunosuppressive drugs, and these
drugs still fail to prevent chronic rejection of the transplanted
organ in many cases. The risk of developing cancer and oppor­
tunistic infections is also markedly increased in solid organ
transplant (SOT) recipients receiving long-term immuno­
suppressive therapy. Cancer and opportunistic infections cannot
be completely avoided since they result from the immuno­
suppressive drugs used posttransplant that affect not only the
anti-graft response but also the entire immune response. Finding
a way to establish donor-speciﬁc immunological tolerance with­
out the need for nonspeciﬁc immunosuppression remains one of
the major goals in transplantation medicine [1,2]. Another
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important aim is the improvement of graft survival and function.
Overall, graft survival is about 15 years, but the increasing
shortage of organs has led to the use of expanded criteria for
donor organs often donated by older individuals, which are less
robust organs than those donated by younger donors.
Mesenchymal stromal cells (MSCs) are currently being eval­
uated in SOT with the hope of achieving more selective immu­
nosuppression, better graft function, and longer graft survival.
56.2 Potential effects of mesenchymal
stromal cells in solid organ
transplantation
Potential MSC beneﬁts to SOT could be mediated through three
main mechanisms: immunomodulation, tissue repair, and anti-
oxidative effects. Moreover, MSCs are able to selectively home to
the sites of tissue injury and inﬂammation, including the intes­
tine, kidney, lung, liver, thymus, and skin [3]. Mechanisms
underlying this homing include interactions between soluble
mediators such as stromal cell-derived factor-1, hyaluronic acid,
macrophage inﬂammatory protein-1(α), hepatocyte growth
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factor (HGF) and their respective MSC receptors, C–X–C che­
mokine receptor type 4 (CXCR4), CD44, C–C chemokine recep­
tor 1, and c-Met [4] (and see Chapters 22 and 23).
56.3 Immunomodulation
The immunosuppressive properties of MSCs have been widely
studied and include inhibition of T cell proliferation and func­
tion, inhibition of dendritic cell (DC) maturation, and induction
of regulatory T cells (Tregs), DCs, and macrophages. For exam­
ple, Bartholomew et al. demonstrated the ability of MSCs to
inhibit lymphocyte proliferation in vitro and to prolong skin
graft survival in vivo [5]. The importance of immunomodulation
by MSCs in SOT is illustrated by the fact that donor-derived,
autologous, and unrelated third-party MSCs seem to have dif­
ferent effects in transplantation models [6]. Transplantation of
human leukocyte antigen (HLA)-nonidentical MSCs is enabled
by their low immunogenicity. However, while some authors
performed mismatched allogeneic MSC transplantation with
no signs of alloreactivity against donor MSCs [7,8], others
observed induction of memory T cell responses and immune
rejection of MSCs in major histocompatibility complex mis­
matched hosts [9–11]. Pretransplant infusion of donor-derived
MSCs may lead to sensitization to donor antigens and hence to
accelerated graft rejection, or, on the contrary, may desensitize
the host to donor antigens. Dosing and timing of MSC infusion
may play a role in this immune balancing act [12]. So far, some
data suggest that MSCs sharing major histocompatibility com­
plex antigens with the donor graft may be superior for inducing
long-term tolerance [6]. The effects of MSCs on the innate
immune system and the adaptive immune system are described
in detail in Chapters 33 and 34 respectively.
56.4 Tissue and organ regeneration
The regenerative effects ofMSCs were initially attributed to their
multilineage differentiation capacity, such as in liver disease in
which MSC administration enabled liver regeneration in animal
models of terminal liver failure or metabolic diseases [13,14].
This could be useful in partial liver transplantation (LT) (split
graft or living donor LT), a technique that is being increasingly
used because of the shortage of donor organs. MSCs also
demonstrated multiple beneﬁcial effects in repairing acute kid­
ney injury in animal models of acute renal failure through
differentiation toward endothelial or smooth muscle cell line­
ages [15] or through a reduction of apoptosis and an increased
proliferation of renal cells [16].
More recently it has been demonstrated that the beneﬁcial
effects of MSCs in these settings are mediated by their ability to
secrete trophic factors that induce proliferation and differentia­
tion of progenitor cells at the site of injury, rather than from
transdifferentiation [6]. For example, allogeneic human MSCs
are able to restore alveolar ﬂuid clearance in human lungs
through the secretion of keratinocyte growth factor [17]. The
importance of these soluble factors secreted by MSCs is also
illustrated by the fact that MSC-conditioned medium (MSC­
CM) has been found effective in reducing inﬂammation and
improving survival in an animal model of LT [18]. Further
information on the MSC secretome is given in Chapters 18
and 19.
56.5 Prevention of ischemia–reperfusion
injury
The term ischemia–reperfusion injury (IRI) deﬁnes inﬂamma­
tory lesions observed when tissues are reperfused after an
ischemic period, as happens after declamping in transplant
surgery. Mechanisms involve endothelium dysfunction with
increased permeability, production of oxygen radicals and
inﬂammatory mediators, and expression of adhesion molecules.
These phenomena lead to a stimulation of both innate and
adaptive immune responses that are responsible for organ
damage [19].
Because of their ability to migrate into hypoxic or inﬂamed
tissues and to downregulate excessive immune responses, the
potential beneﬁcial effects ofMSCs on IRI have been investigated
in animal models of kidney [20–23], liver [24,25], and lung [26]
IRI with promising results. For example, it has been demon­
strated that hyaluronic acid accumulating in the kidney following
ischemic injury stimulates the migration of MSCs through
interaction with the surface receptor CD44 [27]. Complex
paracrine interactions seem involved in this protective effect,
with downregulation of proinﬂammatory signals such as tumor
necrosis factor-α, transforming growth factor-β, interleukin (IL)­
1β, and IL-6 and upregulation of anti-inﬂammatory cytokines
such as IL-10 [24], resulting in MSC-mediated suppression of
oxidative stress and inhibition of apoptosis [25].
56.6 Mesenchymal stromal cell
administration in solid organ
transplantation
56.6.1 Kidney transplantation
Kidney transplantation is the best option for patients suffering
from end-stage kidney diseases, improving survival and quality
of life compared with maintenance dialysis [28,29]. The site of
placement of a transplanted kidney is shown in Figure 56.1.
However, long-term immunosuppressive treatments are nec­
essary to prevent graft rejection. Induction therapy generally
includes an IL-2 receptor antagonist such as basiliximab or a
lymphocyte-depleting agent such as rabbit antithymocyte glob­
ulin (ATG) or muromonab-CD3 (OKT-3). A combination of
immunosuppressive medications is used as maintenance ther­
apy, including calcineurin inhibitors (CNIs) such as tacrolimus
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Figure 56.1 Kidney location after transplantation. Source: nih.gov.
or cyclosporine (CSP), antiproliferative agents such as myco­
phenolate or azathioprine, corticosteroids (prednisolone) and/or
mammalian target of rapamycin inhibitors such as sirolimus or
everolimus. The main causes of posttransplant morbidity and
mortality are cardiovascular diseases, infections, malignancies,
and graft dysfunction.
56.6.1.1 Animal studies
MSCs have demonstrated their ability to downregulate the
immune response after kidney transplantation in several animal
studies. Zhang et al transplanted Lewis rats with Wistar rat
kidney and bone marrow (BM)-MSCs. Intravenous 1× 107 BM-
MSCs were given 1 week before transplantation, immediately
after reperfusion, and 1 and 2 weeks posttransplant and com­
pared with the effects of MSCs alone, CSP alone, and a combi­
nation of MSCs and CSP. They found that MSCs were able to
preserve graft function, as assessed by serum creatinine level, and
to prolong animal survival, but were not as effective as CSP [30].
Monotherapywith third-party BM-MSCs infused directly into
the renal artery of the transplanted kidney (3× 106 cells injected
soon after reperfusion) was studied in a syngeneic and allogeneic
model of rat kidney transplantation. Compared with placebo,
MSC-treated rats had better kidney function as assessed by
serum creatinine level, creatinine clearance rate, proteinuria
and diuresis, reduced histological damage as assessed by the
degree of tubulitis and vasculitis, and a reduced inﬂammatory
inﬁltrate with fewer ED1+ and CD8+ cells [31]. ED1 is a rat
marker of activated monocytes, macrophages, DCs, and micro­
glial cells and is also known as CD68. Tubulitis is a deﬁning
feature for the diagnosis andmanagement of acute renal allograft
rejection.
The efﬁcacy of syngeneic MSCs to prevent IRI was also
demonstrated in a rat kidney transplantation model with pro­
longed cold ischemia. Rats received CSP 1.5mg/kg/per day for 2
days and three intravenous injections of 2.5× 106 or 5.0× 106
MSCs 7 days before, immediately after, and 1 day after
transplantation. MSC administration resulted in reduced intra-
graft gene expression of proinﬂammatory cytokines, chemo­
kines, and intercellular adhesion molecule-1, and in a reduced
inﬁltration of antigen-presenting cells in the renal allograft [32].
The mechanisms of MSC-induced allograft tolerance are not
yet fully elucidated, but generation of Tregs and tolerogenic DCs
and production of indoleamine 2,3-dioxygenase appear to be
involved in mice [33]. The importance of the route of adminis­
tration has been pointed out in rats, as intra-arterial injectionwas
shown to be more efﬁcient than intravenous injection, with a
more rapid functional recovery as assessed by serum creatinine
levels and reduced inﬂammatory inﬁltrate in the graft [34]. These
ﬁndings suggested that a high concentration of MSCs at the site
of immunological injury may be crucial for the efﬁcacy of MSCs
in this setting.
With regard to the timing of MSC administration, experi­
ments in mice have shown that syngeneic MSCs injected intra­
venously after transplantation 2 days posttransplant localized
mainly in the graft, where they were responsible for local
inﬂammatory reaction and failed to enhance graft survival, while
MSCs injected 7 days and 1 day before transplantation localized
in lymphoid organs, promoting Treg expansion and signiﬁcantly
prolonging allograft survival [35]. However, it has been shown in
rats that a delayed third-party MSC injection was also beneﬁcial,
protecting the kidney allograft from injury development as
shown by reduced interstitial ﬁbrosis and tubular atrophy, lower
inﬂammatory cell inﬁltration, and improved balance between
proinﬂammatory and anti-inﬂammatory cytokines [36].
The long-term safety of MSC administration has been ques­
tioned by one group, who observed an unexpected increase in
MSC-related life-threatening events in rats, including throm­
botic microangiopathy, infarctions, and infections [37]. So far
there has been no other report of such MSC-related adverse
events in transplant recipients.
56.6.1.2 Human studies
The ﬁrst studies on human cells showed that in vitro donor-
derived adipose MSCs were able to signiﬁcantly inhibit recipient
antidonor reactivity and proliferation of CD4+ and CD8+ T
lymphocyte subsets in mixed lymphocyte reactions [38]. Com­
bined MSC and hematopoietic stem cell co-transplantation
compared with hematopoietic stem cell transplantation alone
produced signiﬁcantly higher peripheral blood chimerism, better
kidney transplant function as assessed by serum creatinine levels,
and improved survival [39]. Intra-osseous injection of donor
MSCs into the BM at a dose of 1× 106 cells/kg at the time of
kidney transplantation was evaluated in a pilot study of seven
patients undergoing living donor kidney transplantation. The
procedure was safe, but three patients had biopsy-proven acute
rejection that was controlled with corticosteroid pulse therapy.
Donor-speciﬁc T cell proliferation was observed in two patients,
while Treg priming responses were observed in two others
associated with increased IL-10 levels in the peripheral
blood [40].
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56.6.1.3 Mesenchymal stromal cells versus conventional
induction therapy
Perico et al. evaluated the pretransplant infusion of autologous
BM-MSCs in two living-related kidney transplant recipients.
One patient had corticosteroid-sensitive acute cellular rejection
of the kidney 2 weeks posttransplant, but both patients had
excellent renal function at 1 year follow-up. Circulating memory
CD8+ T cell numbers and donor-speciﬁc CD8+ T cell cytolytic
responses were reduced. Compared with patients receiving
basiliximab induction therapy, CD4+ FoxP3+ Treg expansion
was not increased [41].
Tan et al. reported a randomized controlled trial of living
donor kidney transplantation in 156 patients who were divided
into three groups: a control group receiving antibody induction
therapy versus two groups receiving autologous BM-MSCs at a
dose of 1–2× 106/kg administered at the time of kidney graft
reperfusion and 2 weeks later plus either low-dose or standard-
dose CNI treatment. Graft survival was similar, but MSC
infusion resulted in fewer acute rejections at 6 months, no
corticosteroid-resistant rejection, accelerated renal function
recovery, and a reduced rate of opportunistic infections. How­
ever, acute rejection rates and glomerular ﬁltration rates were not
different at 1 year postransplant [42].
56.6.1.4 Mesenchymal stromal cells versus conventional
maintenance therapy
Perico et al. also investigated the effect of autologous BM-MSCs
in two living-related kidney transplant recipients 7 days after
transplantation. Increasing levels of CD4+ CD25high FoxP3+
CD127+ Tregs and inhibition of memory/effector CD8+ T cell
expansion were observed, resulting in a long-term tolerogenic
environment compared with the control group. However,
patients suffered from engraftment syndrome with transient
renal dysfunction a few days after MSC administration, and
biopsies showed a focal inﬂammatory inﬁltrate with neutrophils
and MSCs and complement C3 deposition [43]. (Engraftment
syndrome characterized by fever, rash, pulmonary edema, weight
gain, liver and renal dysfunction, and/or encephalopathy usually
occurs at the time of neutrophil recovery after hematopoietic cell
transplantation).
Another recent pilot study with 12 patients receiving living-
donor related kidneys compared donor-derived BM-MSC infu­
sionswith aﬁrst dose of 5× 106 cells into the renal allograft artery
at the time of kidney transplantation and a second intravenous
dose of 2× 106 cells/kg 1 month later plus low-dose (50% of
usual) tacrolimus versus a control group who received no MSCs
and standard doses of tacrolimus. Patients also received myco­
phenolate mofetil (MMF) and methylprednisolone. All patients
had stable renal function at 1 year posttransplant despite reduced
tacrolimus doses in the MSC group, and only one episode of
acute rejection occurred (in the control group). Signiﬁcantly
increased B cell levels were observed in theMSC group 3months
after transplantation. There were no MSC-related adverse
events [44].
56.6.1.5 Mesenchymal stromal cells as treatment for
kidney rejection
In a phase I trial, Reinders et al. studied two intravenous
infusions of 106 autologous BM-MSCs per kilogram as treatment
for kidney rejection in six patients. MSC infusions were well
tolerated, and no treatment-related serious adverse events were
reported. Biopsies were performed after MSC administration in
two patients and showed resolution of tubulitis without intersti­
tial ﬁbrosis/tubular atrophy. Five patients had downregulation of
peripheral blood mononuclear cell proliferation and three
patients developed an opportunistic viral infection [45].
56.6.1.6 Mesenchymal stromal cells as a desensitizing
treatment
In a report of three cases, infusion of 50× 106 donor-derived
MSCs led to successful desensitization of patients with a positive
lymphocyte cross-match before kidney transplantation [46].
56.6.1.7 Ongoing trials
56.6.1.7.1 Mesenchymal stromal cells in addition to conven­
tional therapy
The Liège trial (NCT01429038) is a single-center, open-label
prospective phase I–II study that includes 10 kidney transplant
recipients receiving a kidney from a deceased donor (and 10 liver
transplant recipients who will be described later). In addition to
induction therapy of standard immunosuppression with anti-IL­
2 antibodies and maintenance therapy of tacrolimus, MMF, and
corticosteroids, patients receive an intravenous infusion of third-
party MSCs at a dose of 1.5–3.0× 106/kg on postoperative day 3
(±2 days). The 10 study patients will be compared at 1 year
posttransplant with a control group of 10 similar kidney trans­
plant recipients. The primary endpoint is safety of the MSC
infusion, including infusional toxicity and incidence of infections
and cancers. Secondary endpoints are patient and graft survival;
graft function assessed by the number of posttransplant hemo­
dialysis episodes required and serum creatinine levels; biopsy-
proven rejection rates using the Banff classiﬁcation; feasibility
and safety of weaning or decreasing immunosuppression, recip­
ient immune function as assessed by T cell blood populations,
including Tregs, T-cell receptor excision circle quantiﬁcation, Vβ
repertoire diversity, pathogen-speciﬁc T cells, anti-organ donor
HLA antibodies; and potential development of anti-MSC donor
HLA antibodies.
The ﬁrst Bergamo trial (NCT00752479) is studying the effects
of syngeneic ex vivo expanded MSCs in HLA-mismatched (one
or two haplotype mismatches) living donor kidney transplanta­
tion. Patients are randomized into two groups. One group
receives an intravenous injection of 2× 106 MSCs/kg at the
time of kidney transplantation. All patients receive conventional
induction treatment with basiliximab, rabbit ATG and methyl­
prednisolone and maintenance treatment with CSP and MMF.
Patients will be followed for 12 months. Primary outcomes
include percentage inhibition of memory and/or naive T cell
responses, induction of donor-reactive T cell anergy, and levels of
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circulating Tregs. Secondary outcomes are safety of the MSC
infusion, graft function, and graft rejection.
The second Bergamo trial (NCT02012153) is investigating the
effect of autologous ex vivo expanded BM-MSCs in HLA-mis­
matched (one or two haplotypemismatches) living donor kidney
transplantation. MSCs are administered intravenously on the
day before kidney transplantation at a dose of 2× 106 MSCs/kg.
Patients are followed for trial parameters for 1 year. Outcomes
evaluated at 6 and 12 months include levels of circulating naive
cells, memory cells, and Tregs, T cell function in mixed lympho­
cyte reaction, urinary forkhead box P3 (FOXP3) mRNA expres­
sion, and adverse events.
56.6.1.7.2 Mesenchymal stromal cells versus conventional
induction therapy
The Fuzhou study (NCT00658073) is evaluating autologous
MSCs as an alternative to antibody induction therapy in renal
transplantation. Patients are randomized into three groups, two
of them receiving two intravenous injections of MSCs immedi­
ately after releasing the renal artery clamp and 2 weeks after
transplantation, while the third group receives standard induc­
tion therapy with anti-IL-2 receptor antibody. All patients will
receive maintenance therapy with CNIs, MMF, and cortico­
steroids, but one of the MSC groups receives a reduced dose
(80% less) of CNIs. Patients will be followed for trial parameters
for 1 year. Primary outcomes are incidence of acute rejection and
early renal function recovery. Secondary outcomes are patient
and graft survival, and prevalence of adverse events.
56.6.1.7.3 Mesenchymal stromal cells versus conventional
maintenance therapy
In a Leiden trial (NCT02057965), intravenous infusions of
autologous BM-MSCs are being evaluated as maintenance ther­
apy in renal transplantation with a kidney from a deceased, a
living unrelated, or a HLA-nonidentical living-related donor
older than 50 years of age. Patients are randomized into two
groups. One group will receive MSCs and everolimus versus
tacrolimus and everolimus. Patients in the MSC group will
receive two injections of 1–2× 106 MSCs/kilogram at 6 and 7
weeks after transplantation. After the second MSC infusion,
tacrolimus is tapered off and withdrawn over a 2-week period.
The primary outcome is kidney ﬁbrosis at 6 months compared
with 4 weeks posttransplant. Secondary outcomes evaluated at
6 months posttransplant are renal function and proteinuria,
complications (including opportunistic infections and cardiovas­
cular disease), adverse effects, a composite endpoint of efﬁcacy
failure (biopsy-proven acute rejection, graft loss, or death, and
immunological parameters such as donor-speciﬁc antibodies.
56.6.1.7.4 Mesenchymal stromal cells as treatment for
kidney rejection
Another Leiden trial (NCT00734396) is studying the safety and
efﬁcacy of autologous BM-MSCs to treat renal transplant rejec­
tion in HLA-DR mismatched kidney graft recipients. Patients
with subclinical rejection and/or an increase in interstitial ﬁbro­
sis/tubular atrophy in the renal biopsy at 4 weeks or 6 months
receive two intravenous injections of 1–2× 106 MSCs/kg 7 days
apart. Primary outcomes are safety and feasibility of MSC
administration at 2 years, while secondary outcomes are efﬁcacy
parameters, including the presence of late acute rejection in the
6-month biopsy compared with the 4-week biopsy, Sirius red
staining for renal cortical matrix accumulation, and immuno­
logic response before and after MSC infusion.
56.6.2 Liver transplantation
Since the pioneering experience in the 1960s LT has become
established as the standard treatment of many end-stage liver
diseases, including cirrhosis, primary liver cancer, fulminant
hepatic failure, and a number of other metabolic or congenital
hepatic diseases. Expected patient survival after LT is now more
than 80% at 1 year and 60–70% at 5 years, dependent on the
different indications for transplantation [47]. The excellent
results of LT have led to a shortage of liver grafts that has
been partially fulﬁlled by the development of living-related
LT, and the procurement of liver grafts from brain-dead donors,
aged cadaveric donors, or donors procured after cardiac
death [48]. A human liver photographed at autopsy is shown
in Figure 56.2.
Immunosuppressive regimens include CNIs, antimetabolites,
mammalian target of rapamycin inhibitors, corticosteroids, and
antibody-based therapies. A combination of CNIs and antime­
tabolites with tapering doses of corticosteroids during the ﬁrst
month is generally used to prevent graft rejection, while treat­
ment of rejection usually comprises boluses of intravenous
corticosteroids or ATG for corticosteroid-resistant rejection.
56.6.2.1 Animal studies
Syngeneic BM-MSCs have shown their ability to home to the
liver and to alleviate acute immunologic rejection in an
orthotopic (normal location) rat LT model [49]. Similarly,
Figure 56.2 Human liver. Source: http://commons.wikimedia.org/wiki/File:
Human_Hepar.jpg#/media/File:Human_Hepar.jpg.
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adipose-tissue-derived MSCs infused intravenously at day  7
and day +3 as well as during the operation via the portal vein
were able to signiﬁcantly decrease acute rejection as assessed by
reduced serum IL-2 levels and increased serum IL-10 levels as
well as reduced hepatocyte apoptosis [50]. MSCs also demon­
strated their efﬁcacy in a liver xenotransplantationmodel (ortho­
topic guinea pig to rat LT), enabling increased survival and
alleviating acute rejection compared with placebo or with the
powerful corticosteroid dexamethasone [51].
MSCs fromdifferent donors have shown equivalent effects in a
rat LT model. Recipient-, donor-, or third-party-derived MSCs
were infused intravenously at the time of surgery and once daily
for 3 days thereafter. MSC administration resulted in signiﬁ­
cantly improved recipient survival, inhibition of allograft rejec­
tion based onhistological analysis and induction ofCD4+CD25+
Foxp3+ Tregs, with no signiﬁcant difference between the three
MSC-treated groups [52].
Du et al. studied the efﬁcacy of the intravenous injection of
MSC-CM in a 50% reduced-size rat LT model. In the MSC-CM
group the authors observed a signiﬁcantly lower release of liver
injury biomarkers, a reduction in hepatocyte apoptosis, an
increased proliferation of hepatocytes and sinusoidal endothelial
cells, and reduced signs of inﬂammation in the graft as assessed
by lower expression of several proinﬂammatory cytokines,
reduced neutrophil inﬁltration and Kupffer cell activation and
increased expression of vascular endothelial growth factor and
matrix metallopeptidase (or metalloproteinase) 9. These obser­
vations were associated with increased survival in the MSC-CM
group compared with the control group [18]. (Kuppfer cells were
ﬁrst observed by Karl Wilhelm von Kupffer in 1876 and are
hepatic macrophages.)
In an attempt to improve MSC homing, the same group used
MSCs overexpressing CXCR4 in a 50% reduced size rat LT
model. MSCs reduced the release of liver injury biomarkers
and apoptosis of hepatocytes. Although unable to further reduce
liver injury, CXCR4 overexpression successfully enhanced MSC
homing and hepatocyte proliferation, resulting in a signiﬁcant
survival beneﬁt [53].
MSCs were also efﬁcient in preventing, but not treating, acute
graft-versus-host disease (GVHD) following LT. Rats that
received donor- or recipient-derived BM-MSCs from day 0 to
day 6 after LT (5× 106 MSCs/day) had a signiﬁcantly longer
survival and no typical LT-associated GVHD symptoms, while
administration of MSCs after the onset of symptoms was
ineffective for treating GVHD. The efﬁcacy of MSC therapy
was associated with higher Treg ratios in the peripheral
blood [54].
Another use of MSCs in LT has been the in vivo delivery of
engineered growth factors or cytokines. Intraportal infusion of
5× 106 syngeneic HGF-expressing MSCs immediately after liver
reperfusion was performed in a 30% small-for-size rat LTmodel.
HGF-expressing MSCs prevented liver failure and improved
liver function and liver weight recovery. Moreover, HGF
enhanced the incorporation of MSCs into injured livers, and
the engrafted cells and their progeny produced albumin [55]. In
another study the same group showed that HGF-expressing
MSCs signiﬁcantly inhibited the formation of liver ﬁbrosis in
rats undergoing small-for-size rat LT with synergistic effects of
the MSCs and HGF [56].
Similarly, genetic delivery of IL-10 by IL-10-engineered-MSCs
has been tested. Comparedwith placebo, intravenous injection of
syngeneic IL-10-transduced MSCs 30min after transplantation
resulted in longer survival, lower Banff scores, increased expres­
sion of the Treg-associated cytokines IL-10 and TGF-β1, and the
transcription factor FOXP3, as well as decreased expression of T
helper (Th)17 T-cell-related cytokines IL-17, IL-6, interferon-γ,
tumor necrosis factor-α, and IL-23 and the retinoic-acid­
related orphan receptor gamma (RORγ) transcription factor
(RORγt) [57]. RORγ is a protein that in humans is encoded
by the RORC (RAR-related orphan receptor C) gene. RORγ is
member of the nuclear receptor family of transcription factors. It
is essential for lymphoid organogenesis, in particular lymph
nodes and Peyer’s patches, but not the spleen. RORγ also plays
an important regulatory role in thymopoiesis, by reducing
apoptosis of thymocytes and promoting thymocyte differentia­
tion into proinﬂammatory Th17 cells. It also plays a role in
inhibiting apoptosis of undifferentiated T cells and promoting
their differentiation into Th17 cells, possibly by downregulating
the expression of Fas ligand and IL2 respectively. RORγt drives
production of the cytokine granulocyte-macrophage colony-
stimulating factor in Th cells, which is essential for the effector
phase of autoimmune neuroinﬂammation.
56.6.2.2 Ongoing trials in humans
The Liège trial (NCT01429038), mentioned earlier, is a single-
center, open-label prospective phase I–II study that includes 10
liver transplant recipients (as well as the 10 kidney transplant
recipients described earlier). In addition to standard immuno­
suppression with tacrolimus, MMF, and corticosteroids, patients
receive an intravenous infusion of third-party MSCs at a dose of
1.5–3.0× 106 MSCs/kg on the third postoperative day (±2 days).
The 10 study patients will be followed for trial parameters for 1
year and compared with a control group of 10 similar liver
recipients. The primary endpoints are safety of theMSC infusion
and the incidence of infections and cancers. The secondary
endpoints are patient and graft survival; graft function as
assessed by serum bilirubin levels, prothrombin time, hepatic
transaminase, and GGT levels; biopsy-proven (Banff classiﬁca­
tion) rejection rates; feasibility and safety of weaning or decreas­
ing immunosuppression; recipient immune function as assessed
by T cell blood populations, including Tregs, T-cell receptor
excision circle quantiﬁcation, Vβ repertoire diversity, pathogen-
speciﬁc T cells, and anti-organ donor HLA antibodies; and
potential development of anti-MSC donor HLA antibodies.
The Beijing trial (NCT01690247) and the Guangdong trial
(NCT02223897) are studying the addition of intravenous injec­
tions of 1× 106 umbilical cord MSCs/kg in addition to conven­
tional therapy. MSCs are administered once every fourth week
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for 12weeks in theﬁrst trial and once perweek for theﬁrstmonth
followed by once per month for 6 months in the second trial.
In the Beijing trial, patients are followed for trial parameters for
48 weeks. Outcomes are rates of acute rejection and early liver
function recovery, patient and graft survival, and incidence of
adverse events. The Guangdong trial is focused on ischemic-type
biliary lesions, and outcomes after 18 months include the inci­
dence of ischemic-type biliary lesions, and changes in hepatic
enzymes and biliary blood supply as assessed by contrast-
enhanced ultrasound examination.
56.6.3 Heart transplantation
Since the ﬁrst human heart transplantation in 1967 this
treatment has been the best option for selected patients
with end-stage heart failure not remediable by more conserv­
ative measures. Despite signiﬁcant improvements in survival
since the introduction of current immunosuppression and
better prevention and treatment of infections, there remain
major complications, including allograft vasculopathy and
other classical complications of solid organ transplantation,
including graft failure, graft rejection, opportunistic infections,
and malignancies.
56.6.3.1 Animal studies
In rats, mesenchymal progenitor cells have demonstrated their
ability to migrate into heart allografts after systemic administra­
tion [58] and to participate in tissue repair during chronic
rejection [59]. The effects of MSC administration on heart
allograft survival are still unknown. Some authors have shown
that in ratsMSCs did not prolong allograft survival [60] and even
accelerated allograft rejection when used alone [61] or when
added to low-dose CSP [62], while other studies demonstrated
increased heart allograft survival using MSCs alone [63–66] or
when MSCs were added to MMF [60,67]. A combination of
MSCs and low-dose sirolimus has enabled long-term heart graft
survival of more than 100 days with normal histology [65]. The
mechanisms of MSC effects on heart allografts are not yet
elucidated, but seem to include CD4+ CD25+ Foxp3+ Treg
and tolerogenic DC expansion [64,65], interferon-γ-induced
suppression of T cell proliferation [60,61], and inhibition of
endothelial activation with intercellular adhesionmolecule 1 and
E-selectin downregulation [61].
No trials in humans have been conducted yet.
56.6.4 Lung transplantation
Single or bilateral lung transplantation is a viable treatment
option for patients with various end-stage lung diseases, such
as chronic obstructive pulmonary disease, idiopathic pulmonary
ﬁbrosis, cystic ﬁbrosis, emphysema due to alpha-1 antitrypsin
deﬁciency, and idiopathic pulmonary arterial hypertension.
Lung transplant recipients are exposed to complications that
include primary graft dysfunction, infections, malignancies,
and both acute and chronic rejection. Chronic lung allograft
manifests as a bronchiolitis obliterans syndrome (BOS).
Endothelin-1-stimulated MSCs may play a pathologic role in
this phenomenon by differentiating locally into myoﬁbroblastic
cells [68]. However, another group demonstrated that resident
lung MSCs isolated from human lung allografts inhibited T cell
proliferation in vitro [69].
There is only one preclinical study of the administration of
MSCs in lung transplantation, and this demonstrated the ability
of IL-10-engineered MSCs to prevent lung IRI in mice [26].
The immunomodulatory properties of MSCs are currently
being assessed in patients with BOS after lung transplantation. In
the Prince Charles Hospital trial in Brisbane, Australia
(NCT01175655), patients with BOS will receive MSCs from
a third-party donor at a dose of 2× 106/kg twice weekly for
2 weeks. Safety, pulmonary function, and survival will be eval­
uated at 12 months. In a Mayo Clinic trial (NCT02181712),
patients with BOS will receive an intravenous injection of
2–4× 106 allogeneic MSCs/kg. Adverse events and pulmonary
function will be assessed after 2 weeks.
56.6.5 Pancreas and islet transplantation
Pancreas or islet transplantation is performed in order to restore
glucose-regulated endogenous insulin secretion, which allows
insulin independence and improves glycemic control in patients
with diabetes mellitus. However, pancreas or islets available for
transplantation are scarce, and long-term pancreatic transplant
survival rates are unsatisfactory, partly due to the lack ofmarkers
for pancreas graft rejection. As in other organ transplantations,
long-term immunosuppression with several drugs is often
required posttransplant.
MSCs have the ability to differentiate into insulin-producing
cells both in vitro [70] and in vivo in animals [71,72] and
humans [73,74]. Moreover, autologous [75], syngeneic [76–78]
or allogeneic [78–80] MSCs have demonstrated immunomodu­
latory properties in animal models of islet transplantation.
Complexmechanisms are involved including secretion of soluble
factors (such as matrix metalloproteinase-2 and -9 [76] and IL­
10 [81]), improvement of graft revascularization [77], and effects
on immune cells (including the inhibition of maturation and
function of DCs [82], downregulation of memory T cells [80],
and induction of regulatory T cells [83]). Moreover, in non­
human primates, co-transplantation of allogeneic donor MSCs
and islet cells led to signiﬁcantly enhanced islet engraftment and
function at 1 month posttransplant, and additional infusions of
donor or third-party MSCs successfully treated rejection [84]. In
addition to these effects, MSCs provide a supportive micro­
environmental niche through the secretion of paracrine factors
and the deposition of extracellular matrix in vitro [85,86], in pre-
transplantation co-cultures [87], and in vivo [88]. Finally, as in
LT, MSCs are able to prevent IRI in animal models of islet
transplantation [89,90].
There is only one ongoing clinical trial on co-transplantation
of allogeneic islets and autologous MSCs. Primary outcomes are
exogenous insulin requirement, glycated hemoglobin, and glu­
cose and C-peptide levels. Secondary outcomes are liver and
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kidney function, portal vein ultrasound appearance, auto­
antibodies, and complete blood count (NCT00646724).
56.6.6 Bowel transplantation
There is one case report of successful administration of third-
party-derived BM-MSCs to treat severe refractory bowel dys­
function secondary to infection after bowel transplantation [91].
More recently, Dog ̆an et al. gave an intra-arterial infusion of
autologous BM-MSCs (three doses of 1× 106 MSCs/kg) at the
time of reperfusion and on days 15 and 30 posttransplant in six
patients undergoing small intestine transplantation. All patients
received anti-thymocyte immunoglobulin and corticosteroids as
induction therapy and a CNI using low-dose tacrolimus as
maintenance therapy. Four patients developed acute rejection.
Three did not survive, of whom one did not respond to bolus
corticosteroid therapy and two developed severe fungal and
bacterial infections after corticosteroids. Two patients did not
experience rejection and had no complications with good quality
of life during the 30 months of trial follow-up [92].
56.7 Conclusions
Studies are providing increasing evidence of MSC beneﬁts in
solid organ transplantation. These beneﬁts appear to be obtained
by a combination of three major properties of MSCs: immuno­
modulation, tissue/organ repair, and prevention of IRI. Complex
mechanisms are involved, and further research is required to
elucidate them. Convincing animal studies in kidney transplan­
tation and LT, and to a lesser extent in lung and islet transplan­
tation, have led to the initiation of human trials. Initial results are
promising in kidney transplantation. In heart transplantation,
conﬂicting data have been obtained and more research is needed
in animal models before human clinical trials can be initiated.
Major goals in this ﬁeld are reduction of graft rejection rates,
improvement of organ and patient survival, and avoidance of
treatment-related adverse effects through dose reduction or
withdrawal of immunosuppressive drugs.
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induced injury. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi therapy in patients with small bowel transplantation: single center
2013;27:910–915. (in Chinese). experience. World J Gastroenterol 2014;20:8215–8220.
